LEADER 02722nam  2200577 a 450 
001 9910790079203321
005 20230725031352.0
010   $a1-283-12126-3
010   $a9786613121264
010   $a0-19-978094-3
035   $a(CKB)2670000000089197
035   $a(EBL)716722
035   $a(OCoLC)729244831
035   $a(SSID)ssj0000526194
035   $a(PQKBManifestationID)12175982
035   $a(PQKBTitleCode)TC0000526194
035   $a(PQKBWorkID)10519688
035   $a(PQKB)11670201
035   $a(MiAaPQ)EBC716722
035   $a(Au-PeEL)EBL716722
035   $a(CaPaEBR)ebr10472263
035   $a(CaONFJC)MIL312126
035   $a(EXLCZ)992670000000089197
100   $a20100331d2011      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$atPA for stroke$b[electronic resource] $ethe story of a controversial drug /$fJustin A. Zivin, John Galbraith Simmons
210   $aNew York $cOxford University Press$d2011
215   $a1 online resource (206 p.)
300   $aDescription based upon print version of record.
311   $a0-19-539392-9 
320   $aIncludes bibliographical references and index.
327   $aCode stroke on Market street -- Clot-buster : the natural history -- Dead or alive -- Brain-O -- The brain doctors cometh : slowly -- What emergency? -- Money and brains -- Deer in the headlights -- Call 911, 112, 15 ... even 999 -- Persistence of a most controversial drug -- Through the looking glass -- Post-script.
330   $aWithout warning stroke can paralyze, blind, or kill. Some victims recover, but many do not and may even suffer another disabling or fatal attack. The drug known as tPA can drastically reduce the long-term disability associated with stroke, but despite its near-miraculous capabilities and the growing support of most neurologists, it has been slow to win acceptance as the standard of care in emergency departments nationwide. tPA for Stroke chronicles how this remarkable drug came to be tested in stroke victims, its early years in development by the pharmaceutical giant Genentech, and its eventua
606   $aCerebrovascular disease$xChemotherapy$xHistory
606   $aTissue plasminogen activator$xTherapeutic use$xHistory
615  0$aCerebrovascular disease$xChemotherapy$xHistory.
615  0$aTissue plasminogen activator$xTherapeutic use$xHistory.
676   $a616.8/106
700   $aZivin$b Justin A$01511018
701   $aSimmons$b John$f1949-$01511019
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910790079203321
996   $aTPA for stroke$93744052
997   $aUNINA